TY - JOUR
T1 - Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan
AU - Hemmersbach-Miller, Marion
AU - Balevic, Stephen J.
AU - Winokur, Patricia L.
AU - Landersdorfer, Cornelia B.
AU - Gu, Kenan
AU - Chan, Austin W.
AU - Cohen-Wolkowiez, Michael
AU - Conrad, Thomas
AU - An, Guohua
AU - Kirkpatrick, Carl M.J.
AU - Swamy, Geeta K.
AU - Walter, Emmanuel B.
AU - Schmader, Kenneth E.
N1 - Funding Information:
This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, through Contract No. HHSN272201500002C (Emmes), and a Vaccine and Treatment Evaluation Units award under Contract No. HHSN272201300017I (Duke University) and Contract No. HHSN2722013000201 (University of Iowa). This work was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (grant number 5T32AI100851 to MHM). KES also received support from the National Institute on Aging, Duke Pepper Older Americans Independence Center, NIA P30AG028716. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. MCW receives support for research from the NIH [1U24-MD016258], National Institute of Allergy and Infectious Diseases [HHSN272201500006I, HHSN272201300017I, 1K24-AI143971], NICHD [HHSN275201000003I], US Food and Drug Administration [5U18-FD006298], and industry for drug development in adults and children.
Funding Information:
SJB receives support from the National Institutes of Health, the US Food and Drug Administration, the Patient-Centered Outcomes Research Institute, the Rheumatology Research Foundation’s Scientist Development Award, the Childhood Arthritis and Rheumatology Research Alliance, Purdue Pharma, and consulting for UCB. The remaining authors have no relevant disclosures.
Publisher Copyright:
© 2022, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2023/1/12
Y1 - 2023/1/12
N2 - Background and Objective: Piperacillin/tazobactam is one of the most frequently used antimicrobials in older adults. Using an opportunistic study design, we evaluated the pharmacokinetics of piperacillin/tazobactam as a probe drug to evaluate changes in antibacterial drug exposure and dosing requirements, including in older adults. Methods: A total of 121 adult patients were included. The population pharmacokinetic models that best characterized the observed plasma concentrations of piperacillin and tazobactam were one-compartment structural models with zero-order input and linear elimination. Results: Among all potential covariates, estimated creatinine clearance had the most substantial impact on the elimination clearance for both piperacillin and tazobactam. After accounting for renal function and body size, there was no remaining impact of frailty on the pharmacokinetics of piperacillin and tazobactam. Monte Carlo simulations indicated that renal function had a greater impact on the therapeutic target attainment than age, although these covariates were highly correlated. Frailty, using the Canadian Study of Health and Aging Clinical Frailty Scale, was assessed in 60 patients who were ≥ 65 years of age. Conclusions: The simulations suggested that adults ≤ 50 years of age infected with organisms with higher minimum inhibitory concentrations may benefit from continuous piperacillin/tazobactam infusions (12 g/day of piperacillin component) or extended infusions of 4 g every 8 hours. However, for a target of 50% fT + minimum inhibitory concentration, dosing based on renal function is generally preferable to dosing by age, and simulations suggested that patients with creatinine clearance ≥ 120 mL/min may benefit from infusions of 4 g every 8 hours for organisms with higher minimum inhibitory concentrations.
AB - Background and Objective: Piperacillin/tazobactam is one of the most frequently used antimicrobials in older adults. Using an opportunistic study design, we evaluated the pharmacokinetics of piperacillin/tazobactam as a probe drug to evaluate changes in antibacterial drug exposure and dosing requirements, including in older adults. Methods: A total of 121 adult patients were included. The population pharmacokinetic models that best characterized the observed plasma concentrations of piperacillin and tazobactam were one-compartment structural models with zero-order input and linear elimination. Results: Among all potential covariates, estimated creatinine clearance had the most substantial impact on the elimination clearance for both piperacillin and tazobactam. After accounting for renal function and body size, there was no remaining impact of frailty on the pharmacokinetics of piperacillin and tazobactam. Monte Carlo simulations indicated that renal function had a greater impact on the therapeutic target attainment than age, although these covariates were highly correlated. Frailty, using the Canadian Study of Health and Aging Clinical Frailty Scale, was assessed in 60 patients who were ≥ 65 years of age. Conclusions: The simulations suggested that adults ≤ 50 years of age infected with organisms with higher minimum inhibitory concentrations may benefit from continuous piperacillin/tazobactam infusions (12 g/day of piperacillin component) or extended infusions of 4 g every 8 hours. However, for a target of 50% fT + minimum inhibitory concentration, dosing based on renal function is generally preferable to dosing by age, and simulations suggested that patients with creatinine clearance ≥ 120 mL/min may benefit from infusions of 4 g every 8 hours for organisms with higher minimum inhibitory concentrations.
UR - https://www.scopus.com/pages/publications/85146171459
U2 - 10.1007/s40262-022-01198-z
DO - 10.1007/s40262-022-01198-z
M3 - Article
C2 - 36633812
AN - SCOPUS:85146171459
SN - 0312-5963
VL - 62
SP - 127
EP - 139
JO - Clinical Pharmacokinetics
JF - Clinical Pharmacokinetics
ER -